Clinical Trials
124
17 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1872
Active, not recruiting
5
4.0%
Completed
83
66.9%
Enrolling By Invitation
5
4.0%
Not yet recruiting
7
5.7%
Recruiting
16
12.9%
Terminated
5
4.0%
Withdrawn
3
2.4%
No approval data available
- Researchers at Virginia Tech's Fralin Biomedical Research Institute identified BMP3 as a natural protective protein that maintains healthy lung blood vessels and is significantly reduced in pulmonary arterial hypertension. - Two therapeutic strategies—recombinant BMP3 protein and lung-targeted gene therapy—both reversed key disease features including pulmonary vascular remodeling and heart dysfunction in preclinical models. - Circulating BMP3 levels were consistently lower in PAH patients, suggesting potential utility as both a therapeutic target and a disease-monitoring biomarker. - The findings reveal a previously unrecognized pathway in PAH and point to the first treatment strategy aimed at reversing underlying vascular remodeling rather than merely managing symptoms.
- Virginia Tech, UVA, VCU, and Old Dominion University launched the Biomedical Research Diamond to accelerate translation of discoveries into patient care. - The partnership combines expertise in basic science, engineering, clinical research, pharmaceutical development, and manufacturing that no single institution possesses. - Researchers presented advances spanning neuroscience, cancer, rare diseases, cardiovascular health, immunology, artificial intelligence, and drug discovery. - Leaders emphasized the initiative aims to retain scientific talent in Virginia while strengthening national security and economic competitiveness.
- Five Fralin Biomedical Research Institute at VTC faculty members received tenure during a June Virginia Tech Board of Visitors meeting, including four promotions to associate professor with tenure. - William "Matt" Howe's research has identified distinct neurochemical signatures differentiating Parkinson's disease from essential tremor, two of the most common neurological movement disorders. - Yassine Sassi's work on coding and non-coding RNAs and cyclic nucleotide pathways has generated mechanistic insights into pulmonary fibrosis, a disease that currently has no effective treatment. - Alexandra DiFeliceantonio and Jeffrey Stein co-direct the Center for Health Behaviors Research, studying ultra-processed foods and behavioral economics approaches to smoking and overeating.
- Virginia Tech researchers received a $460,260 National Institute on Aging grant to use artificial intelligence to improve pain assessment and clinical decision-making for rural older adults with chronic pain. - An estimated 36 percent of U.S. adults over age 65 experience pain most days or every day, with rural communities facing reduced access to pain specialists and healthcare resources. - The interdisciplinary team will apply machine learning and natural language processing to extract pain information buried in clinical notes and build risk dashboards for complications such as depression and cognitive impairment. - Digital tools, including symptom-tracking apps, neuromodulation devices, and FDA-approved virtual reality systems, are emerging as complementary approaches to individualized chronic pain management.
- Prescriptions for ivermectin and fenbendazole among cancer patients rose 2.5-fold in early 2025 following Mel Gibson's claims on The Joe Rogan Experience, according to a JAMA Network Open study. - Researchers analyzed health records from over 68 million patients and found the steepest increases among white men and patients in the South, groups overlapping with Rogan's audience. - No human clinical trials have demonstrated that ivermectin or fenbendazole are safe or effective for treating cancer, and experts warn patients may forgo proven therapies. - The findings highlight the growing challenge of celebrity-driven health misinformation in an era where half of U.S. adults under 50 get health information from influencers.
